Dr. Lal Pathlabs Ltd

NSE: LALPATHLAB · BSE: 539524 · Healthcare · 17 announcements

Share price: ₹1,952.30
Market cap: ₹32,769 Cr
Revenue (annual): ₹2,763 Cr
Net profit (annual): ₹504.8 Cr
P/E (TTM): 60.5×Sector 57.8×
Promoter holding: 53.19%-0.02% QoQ
FII holding: 17.35%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

Announcement type

All Acquisition 4 Other Announcement 3 Employee Stock Options 1 Capital Structure Change 1 Board Meeting Date 1

Time

All time Last 1 week Last 1 month Last 2 months Last 3 months Last 6 months Last 1 year

4 announcements with these filters

26 Sep 2026 17:07 IST NSE

Acquisition

Dr. Lal Pathlabs Acquisition Worth ₹38 Cr

Dr. Lal Path Labs' subsidiary completed the acquisition of an 80% stake in Sunshine Healthcare Limited, Ghana, for Rs.38.00 Crore. The target is now a subsidiary.

Value: ₹38.00 Cr

Read the filing ↗

26 Sep 2026 16:54 IST NSE

Acquisition

Dr. Lal Pathlabs Acquisition

Dr. Lal PathLabs' subsidiary, DLPL Dubai, completed the acquisition of an 80% stake in Sunshine Healthcare Limited, Ghana. Sunshine Healthcare is now a step-down subsidiary.

Read the filing ↗

24 Sep 2026 18:49 IST BSE

Acquisition

Dr. Lal Pathlabs Acquisition Worth ₹168 Cr

Dr. Lal Path Labs Ltd. will acquire a 70% stake in SN Genelab Private Limited for Rs. 168 Crore to strengthen its genomics diagnostics portfolio.

Value: ₹168.0 Cr

Read the filing ↗

24 Sep 2026 17:20 IST BSE

Acquisition

Dr. Lal Pathlabs Acquisition Worth ₹199.5 Cr

Dr. Lal PathLabs approved the acquisition of a 70% stake in SN Genelab Private Limited for a total consideration of up to ₹199.5 Crore.

Value: ₹199.5 Cr

Read the filing ↗